Increased prevalence of subclinical atherosclerosis in patients with hidradenitis suppurativa (HS) - 20/07/16
Abstract |
Background |
Chronic inflammatory diseases have been associated with increased prevalence of subclinical atherosclerosis. Hidradenitis suppurativa (HS) is a chronic inflammatory disease involving intertriginous skin.
Objective |
We sought to investigate the potential association between HS and subclinical atherosclerosis.
Methods |
This study included 68 patients with HS and 136 age- and sex-matched healthy control subjects. Patients with history of cardiovascular events, diabetes mellitus, chronic kidney disease, or another concomitant inflammatory condition were excluded. Carotid intima-media thickness and carotid plaques were measured by carotid ultrasonography. Adjustments were made for age, sex, and traditional cardiovascular risk factors.
Results |
Patients had greater carotid intima-media thickness values than control subjects (0.615 ± 0.097 vs 0.578 ± 0.098 mm; P = .012). Carotid plaques were also more frequent in patients than in control subjects (30.9% vs 22.1%). In the multivariable regression model adjusted for age, sex, and traditional cardiovascular risk factors, HS was significantly related to the presence of carotid plaques (odds ratio 2.99, 95% confidence interval 1.26-7.13; P = .013).
Limitations |
Causality could not be assessed.
Conclusions |
These results indicate an increased frequency of subclinical atherosclerosis in patients with HS. Accordingly, HS should be considered a disease associated with potentially increased cardiovascular risk.
Le texte complet de cet article est disponible en PDF.Key words : cardiovascular disease, carotid intima-media thickness, carotid plaque, carotid ultrasonography, hidradenitis suppurativa, subclinical atherosclerosis
Abbreviations used : BMI, BP, cIMT, CVD, HDL-c, HS, LDL-c, PGA
Plan
Drs González-Gay and Blanco share senior authorship. |
|
Supported by an unrestricted grant from Abbvie Inc. |
|
Disclosure: Dr González-Gay received grant funding from Abbvie. Drs González-López, Hernández, Lacalle, Mata, López-Escobar, López-Mejías, Corrales, González-Vela, and Blanco, Ms Portilla, and Ms Fuentevilla have no conflicts of interest to declare. The opinions expressed in this article are those of the authors and do not necessarily represent those of Abbvie Inc. |
Vol 75 - N° 2
P. 329-335 - août 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?